ContributorsPublishersAdvertisers

AstraZeneca

AstraZeneca, Daiichi Sankyo drug, Keytruda combo shows promise in early stage lung cancer trial

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) said their medicine datopotamab deruxtecan (Dato-DXd) in combination with Merck's (MRK) Keytruda (pembrolizumab), with or without platinum chemotherapy, showed promising clinical activity and a tolerable safety profile in certain patients with a type of lung cancer. The study, dubbed TROPION-Lung02, evaluated the drug...
MEDICAL & BIOTECH
Picture for AstraZeneca, Daiichi Sankyo drug, Keytruda combo shows promise in early stage lung cancer trial
biopharmadive.com

Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug

A drug combination involving an experimental treatment from AstraZeneca and Daiichi Sankyo has shown early promise in lung cancer, results the two companies believe bolster their recent decision to start a late-stage trial. Study results presented at the World Conference for Lung Cancer show that a regimen of the companies’...
CANCER
Picture for Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug

AstraZeneca cancer drug Calquence's tablet form gets FDA approval

AstraZeneca (NASDAQ:AZN) said on Aug. 5 that the U.S. Food and Drug Administration (FDA) approved a new tablet formulation of Calquence (acalabrutinib) for all current uses. The approval covers all indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate.
INDUSTRY
Picture for AstraZeneca cancer drug Calquence's tablet form gets FDA approval
RELATED PEOPLE

AstraZeneca, Hutchmed savolitinib/ Tagrisso combo shows response in some lung cancer patients

AstraZeneca (NASDAQ:AZN) said its drug Tagrisso and savolitinib, developed with Hutchmed (China) (NASDAQ:HCM), showed response in certain patients with non-small cell lung cancer (NSCLC) in a phase 2 trial called SAVANNAH. Tagrisso (osimertinib) plus savolitinib showed an objective response rate (ORR) of 49% in patients with epidermal growth factor receptor-mutated...
CANCER
Nature.com

Untangling the web of intratumour heterogeneity

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and disease progression. Technological and computational advances have enabled us to assess ITH at unprecedented depths, yet this accumulating knowledge has not had a substantial clinical impact. This is in part due to a limited understanding of the functional relevance of ITH and the inadequacy of preclinical experimental models to reproduce it. Here, we discuss progress made in these areas and illuminate future directions.
SCIENCE
StreetInsider.com

AstraZeneca (AZN) Reports Tagrisso plus Savolitinib Demonstrated 49% Objective Response Rate in SAVANNAH Phase II Trial

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Preliminary results from AstraZeneca's (NASDAQ: AZN) SAVANNAH Phase II trial showed that Tagrisso (osimertinib) plus savolitinib demonstrated an objective response rate (ORR) of 49% (95% confidence interval [CI], 39-59%) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with Tagrisso.
MEDICAL & BIOTECH
RELATED PUBLISHERS
YOU MAY ALSO LIKE